Anzeige
Mehr »
Login
Donnerstag, 23.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Amazon investiert Millionen in Kernenergie - so können Sie sich früh positionieren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14XDG | ISIN: FR0012872141 | Ticker-Symbol: 6XW
Frankfurt
23.01.25
08:02 Uhr
5,660 Euro
-0,020
-0,35 %
Branche
Kosmetik
Aktienmarkt
Sonstige
1-Jahres-Chart
JACQUES BOGART SA Chart 1 Jahr
5-Tage-Chart
JACQUES BOGART SA 5-Tage-Chart
RealtimeGeldBriefZeit
5,6005,92016:32
Actusnews Wire
402 Leser
Artikel bewerten:
(2)

GROUPE BOGART: H1 2024 turnover: EUR 133.5 million

Finanznachrichten News

PRESS RELEASE

Paris, 25 July 2024

Revenues in €m (unaudited)20232024Change %
H1 turnover137.6133.5-3.0%
Bogart Fragrances & Cosmetics27.826.4-5.0%
Bogart Beauty Retail109.8107.1-2.5%
Other H1 revenues[1]5.85.8-
Total H1 revenues143.4139.3-2.9%

H1 turnover at constant consolidation scope and exchange rates

Revenues in €m20232024Change %
H1 turnover132.1131.1-0.8%
Bogart Fragrances & Cosmetics27.325.9-5.1%
Bogart Beauty Retail104.8105.2+0.4%
Other H1 revenues15.85.80.0%
Total H1 revenues137.9136.9-0.7%

H1 business

In the first half of 2024, Bogart held up well in a less buoyant global economic environment. Turnover came to €133.5m, down by a slight -3.0% at current exchange rates compared with H1 2023 and practically stable at constant consolidation scope and exchange rates (-0.8%).

Bogart Fragrances & Cosmetics generated turnover of €26.4m in H1 2024, down -5.0% compared with H1 2023 which represented a high comparison base and with no new launches for the Group's key brands. However, over the first six months, Bogart consolidated initial revenue from its new Rose et Marius brand (acquired in January 2024[2]), which enjoyed a very good start-up in the store network in France and Belgium, enabling the group to offset the mechanical decline in turnover in Spain following the change in business model of the subsidiary (refocusing on indirect sales, generating structural cost savings). At constant consolidation scope and exchange rates, turnover was down -5.1%.

Turnover generated by Bogart Beauty Retail came to €107.1m in H1 2024, down a slight -2.5% compared with H1 2023 which still factored in the revenue from a few stores in France which have since been closed (as part of the reorganisation carried out in France in H1 2023 - of the 17 stores concerned, 4 were closed at the end of the period). Note also certain scope effects over the period, in Dubai (at the start of the year, the Group refocused on three stores in Dubai, instead of six, as part of its strategy to optimise profitability) and in Germany (9 independent fragrance stores integrated in the HC Parfumerie network from 1 March 2024). At constant consolidation scope and exchange rates, growth in turnover was slightly positive (+0.4%).

2024 outlook

For 2024, Bogart remains committed to its profitable growth strategy, propelled by its two divisions, namely Bogart Fragrances & Cosmetics and Bogart Beauty Retail.

In H2 2024, Bogart will launch its new fragrances and cosmetics in its different ranges and also benefit from the anticipated growth of its new brand Rose et Marius in its own-brand distribution network and via its international network of distributors.

Bogart wants to focus its efforts on expanding its margins in its two main areas of business and thus favour higher value-added turnover. As part of this strategy, the Group will notably continue its work on the type of products deployed in its own-brand store network, with a more premium and selective positioning. This new strategy, which has already been introduced in Israel and is paying off, will be adopted in Germany and Slovakia and then gradually rolled out to other geographies.

In fragrances, the Jacques Bogart "Silver Scent AQUA" brand should continue to enjoy global growth, while Carven will launch a new eau de toilette and a new eau de parfum, "Carven C'est Paris Elixir".

Regarding cosmetics, in the second half-year, STENDHAL will innovate by unveiling an all-new line of exceptional skincare products branded as Divine Alba. The Méthode Jeanne Piaubert, April and Close brands will continue expanding, with more than 20 new products set for release from the end of Q3. Lastly, in the autumn, BOGART will unveil its 10th brand with a new exceptional fragrance.

Next publication

H1 2024 results: Thursday 26 September 2024 (after market)

Group website www.groupe-bogart.com

CONTACTS

BOGART

contact@jbogart.com

Tel.: 01 53 77 55 55

ACTUS FINANCE & COMMUNICATION

Investor relations

Anne-Pauline Petureaux

apetureaux@actus.fr

Tel.: +33 (0)1 53 67 36 72

Media Relations

Manon Clairet
mclairet@actus.fr

Tel.: +33 (0)1 53 67 36 73


[1] Revenue from licences and advertising rebillings for brands which are distributed to Bogart's own-brand networks.

[2] See 15 January 2024 press release

------------------------
This publication embed "Actusnews SECURITY MASTER".
- SECURITY MASTER Key: nJqfZchql5eUm25paZZtm5ZomGmXlWTFZZKdxmWZlpyVbGtolGZmm8WdZnFolWpm
- Check this key: https://www.security-master-key.com.
------------------------
Full and original release in PDF format:
https://www.actusnews.com/documents_communiques/ACTUS-0-87050-pr_bogart_q2_2024_final.pdf

© Copyright Actusnews Wire
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
© 2024 Actusnews Wire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.